Overview

Detailed Summary

Metropolis Healthcare Limited is a pan-India clinical diagnostics company operating a large hub-and-spoke laboratory network, offering routine to super-specialty tests, genomics, B2C and B2B services, preventive wellness (TruHealth) and institutional clinical research support across India and selected international markets.
Q3 FY26 organic revenue grew 15% to INR 371 crore with EBITDA of INR 93 crore and margin expansion to 25%, while Group revenue grew 26% to INR 406 crore; PAT excluding exceptional items rose meaningfully, reflecting improving mix, productivity initiatives and economies of scale.
Metropolis is actively premiumising revenue via TruHealth and specialty testing: TruHealth grew ~25% and now contributes 19% of organic revenue, while specialty contribution rose to ~38% driven by genomics, NGS test additions, clinician engagement and AI-enabled interpretation.
Network scale and disciplined M&A are central: the company operates 219 labs and ~4,862 centres, added ~112 centres in Q3, completed four acquisitions (including Core Diagnostics) and launched a Centre of Genomics with Illumina partnership to capture higher-value testing demand.
Financially conservative posture: Metropolis remains net debt-free with cash ~INR 127 crore, FY26 capex guidance of INR 55–60 crore focused on labs, IT and advanced equipment, and the Board approved a 3:1 bonus share proposal signalling confidence in liquidity and shareholder alignment.

Sector: Healthcare
Industry: Diagnostic Services
Market Cap: 9,572 Cr
Volatility: Low Risk
P/E Ratio: 57.1
Industry P/E: 42.1
PEG Ratio: 2.6
P/B Ratio: 6.7
52W High: 2,259.30
52W Low: 1,383.70

Sales CAGR

1Y: 10.23%
3Y: 1.69%
5Y: 12.83%
10Y: —

Profit CAGR

1Y: 13.27%
3Y: -14.48%
5Y: 2.18%
10Y: —

ROE

TTM: 11.05%
3Y: 12.14%
5Y: 16.19%
10Y: —

ROCE

TTM: 14.12%
3Y: 15.08%
5Y: 19.29%
10Y: —

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
VIJAYA	935.00	9,663 Cr	60.30	11.17	0.21	17.53	18.98	11.50
METROPOLIS	1850.00	9,572 Cr	57.13	6.68	0.00	11.05	14.12	8.50
THYROCARE	374.95	5,990 Cr	43.37	11.21	1.86	23.91	34.14	19.95
KRSNAA	609.60	1,951 Cr	24.97	2.11	0.46	9.16	11.09	5.34
VIMTALABS	428.00	1,918 Cr	31.55	5.60	0.23	14.59	19.04	13.94
SURAKSHA	270.00	1,384 Cr	42.25	6.01	0.00	13.86	14.74	8.53
ONEGLOBAL	595.05	1,163 Cr	23.72	11.48	0.00	43.51	58.07	27.58

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	309	291	331	313	350	323	345	386	429	406
Expenses	234	226	251	235	260	251	283	296	321	311
Operating Profit	75	65	80	79	90	72	62	90	108	95
OPM %	24.25	22.28	24.16	25.15	25.70	22.31	18.04	23.25	25.22	23.37
Other Income	1.22	2.31	2.54	2.46	3.13	2.56	6.97	7.52	0.89	-0.08
Interest	5.68	5.31	5.57	4.65	4.79	4.53	4.60	5.20	5.68	5.73
Depreciation	22	25	26	26	27	28	29	31	32	32
Profit Before Tax	48	37	51	51	61	42	36	61	71	57
Tax %	25.88	25.97	27.73	25.39	23.94	25.65	18.90	26.11	25.54	26.36
Net Profit	36	27	37	38	47	31	29	45	53	42
EPS in Rs	6.82	5.22	7.00	7.29	8.93	6.02	5.66	8.66	10.13	7.94

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	647	761	856	998	1,228	1,148	1,208	1,331	1,404
Expenses	471	561	624	712	886	860	925	1,028	1,090
Operating Profit	176	200	233	286	343	288	283	303	314
OPM %	27.22	26.32	27.19	28.66	27.91	25.11	23.40	22.76	22.36
Other Income	7.77	6.78	-16	12	34	15	9.12	15	20
Interest	1.21	0.53	8.34	7.78	20	27	23	19	19
Depreciation	19	20	39	46	63	89	94	109	114
Profit Before Tax	164	187	169	244	293	188	175	191	201
Tax %	31.67	33.74	24.41	24.96	26.82	23.52	26.47	23.76	24.06
Net Profit	112	124	128	183	215	143	128	146	153
EPS in Rs	—	24.01	24.54	35.28	41.14	27.47	24.58	27.90	32.38
Dividend Payout %	0.00	55.20	31.68	22.35	19.20	28.77	16.08	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	9.54	10	10	10	10	10	10	10
Reserves	405	409	513	696	876	978	1,086	1,321
Borrowings	0.57	18	67	112	379	266	197	204
Other Liabilities	115	116	162	186	266	247	262	332
Total Liabilities	530	553	752	1,004	1,530	1,502	1,555	1,867
Fixed Assets	207	213	296	343	1,059	1,121	1,177	1,447
CWIP	0.00	5.77	2.99	0.00	5.78	20	0.00	0.00
Investments	102	33	14	10	16	15	55	71
Other Assets	221	301	439	651	450	347	323	349
Total Assets	530	553	752	1,004	1,530	1,502	1,555	1,867

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	104	90	215	249	253	247	264	263
Cash from Investing Activity	1.10	35	-105	62	-735	47	-89	-200
Cash from Financing Activity	-87	-118	-55	-33	163	-292	-181	-87
Net Cash Flow	18	7.35	55	278	-319	1.56	-6.54	-24

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	49.75%	49.75%	49.74%	49.74%	49.67%	49.62%	49.43%	49.40%	48.90%	48.89%	48.89%	48.88%
FIIs	25.67%	25.66%	24.29%	21.66%	18.90%	18.25%	18.56%	16.73%	15.29%	12.83%	12.52%	11.69%
DIIs	13.64%	14.89%	16.86%	20.73%	24.86%	27.43%	28.02%	30.00%	30.30%	32.40%	33.10%	34.73%
Public	10.94%	9.70%	9.11%	7.87%	6.57%	4.70%	3.99%	3.87%	5.52%	5.88%	5.49%	4.71%
Total Shareholders	84,269	89,692	86,249	79,878	68,283	58,108	51,852	48,572	49,293	50,015	47,846	46,670

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Available on Pro Plan